A5011138537- Ovarian cancer diagnosis and treatment
- Renal cell carcinoma treatment
- Intraperitoneal and Appendiceal Malignancies
- Sarcoma Diagnosis and Treatment
- Management of metastatic bone disease
- Reproductive Biology and Fertility
- Cancer Diagnosis and Treatment
- Cancer Mechanisms and Therapy
MRC Clinical Trials Unit at UCL
2017-2022
University College London
2017-2022
Medical Research Council
2021
Standard-of-care first-line chemotherapy for epithelial ovarian cancer is carboplatin and paclitaxel administered once every 3 weeks. The JGOG 3016 trial reported significant improvement in progression-free overall survival with dose-dense weekly 3-weekly (ie, weeks) carboplatin. However, this benefit was not observed the previously results of ICON8. Here, we present final coprimary outcomes updated analyses
•Cediranib is an oral VEGF receptor kinase inhibitor and ICON6 explored its activity in recurrent ovarian cancer.•In a randomised trial cediranib with chemotherapy as maintenance significantly prolonged PFS.•Cessation of supply led to reduction sample size OS was underpowered.•A mature survival analysis showed non-significant increase the median Restricted Mean Survival Time (RMST) cediranib.•There clinical benefit but further research needed determine role cancer. BackgroundCediranib,...
5506 Background: ICON6 is a three-arm double-blind, placebo-controlled phase 3 trial of cediranib in platinum-sensitive relapsed ovarian cancer (NCT00532194). The primary analysis (Ledermann et al Lancet 2016) showed significant (p < 0.0001), 2.3 month extension progression-free survival (PFS) using with chemotherapy and as maintenance compared to placebo. We present the final overall (OS) results. Methods: was originally designed recruit 2000 patients OS endpoint. AstraZeneca...
Background: The ICON6 trial (ISRCTN68510403) is a phase III academic-led, international, randomized, three-arm, double-blind, placebo-controlled of the addition cediranib to chemotherapy in recurrent ovarian cancer. It investigated use placebo during and maintenance (arm A), alongside followed by B) throughout both periods C). Results primary comparison showed meaningful gain progression-free survival (time progression or death from any cause) when comparing arm A (placebo) with C...
Background The quality of life (QoL) patients with osteosarcoma (OS) may be adversely affected by the disease or its treatment. Therefore, it is important to understand QoL undergoing treatment for OS improve QoL. We report on first prospective international study that was embedded within a large randomized clinical trial from 4 national groups. Objective This paper aimed describe development, methodology, accrual details, and characteristics cohort. Methods A total 2260 registered in...